Proapoptotic fibronectin fragment induces the degradation of ubiquitinated p53 via proteasomes in periodontal ligament cells

Journal of Periodontal Research

Volumn 45, Issue 4, 2010, Pages 481-487

  Ghosh, A ^a   Joo, N E ^a   Chen, T C ^a   Kapila, Yvonne L ^a  

^a UNIVERSITY OF MICHIGAN SCHOOL OF DENTISTRY   (United States)

Author keywords

Extracellular matrix; Fibronectin; P53; Periodontitis; Proteasome; Ubiquitin

Indexed keywords

ACETYLCYSTEINE; BENZYLOXYCARBONYLLEUCYL LEUCYL LEUCINE ALDEHYDE; BENZYLOXYCARBONYLLEUCYL-LEUCYL-LEUCINE ALDEHYDE; CYSTEINE PROTEINASE INHIBITOR; DRUG DERIVATIVE; FIBRONECTIN; ISOPROTEIN; LACTACYSTIN; LEUPEPTIN; PEPTIDE FRAGMENT; PROTEASOME; PROTEIN P53; RECOMBINANT PROTEIN; SMALL INTERFERING RNA; UBIQUITIN;

APOPTOSIS; ARTICLE; CELL CULTURE; CULTURE TECHNIQUE; CYTOLOGY; DOWN REGULATION; DRUG EFFECT; GENETIC TRANSFECTION; GENETICS; HUMAN; METABOLISM; MUTATION; PERIODONTAL LIGAMENT; PHYSIOLOGY; PROTEIN PROCESSING;

ACETYLCYSTEINE; APOPTOSIS; CELL CULTURE TECHNIQUES; CELLS, CULTURED; CYSTEINE PROTEINASE INHIBITORS; DOWN-REGULATION; FIBRONECTINS; HUMANS; LEUPEPTINS; MUTATION; PEPTIDE FRAGMENTS; PERIODONTAL LIGAMENT; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN ISOFORMS; PROTEIN PROCESSING, POST-TRANSLATIONAL; RECOMBINANT PROTEINS; RNA, SMALL INTERFERING; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITIN;

EID: 77954838956     PISSN: 00223484     EISSN: 16000765     Source Type: Journal    
DOI: 10.1111/j.1600-0765.2009.01261.x     Document Type: Article

References (35)

1. Homandberg GA, Wen C, Hui F. Cartilage damaging activities of fibronectin fragments derived from cartilage and synovial fluid. Osteoarthritis Cartilage 1998, 6:231-244.
2. Huynh QN, Wang S, Tafolla E. Specific fibronectin fragments as markers of periodontal disease status. J Periodontol 2002, 73:1101-1110.
3. Talonpoika J, Heino J, Larjava H, Hakkinen L, Paunio K. Gingival crevicular fluid fibronectin degradation in periodontal health and disease. Scand J Dent Res 1989, 97:415-421.
4. Talonpoika J, Paunio K, Soderling E. Molecular forms and concentration of fibronectin and fibrin in human gingival crevicular fluid before and after periodontal treatment. Scand J Dent Res 1993, 101:375-381.
5. Xie D, Homandberg GA. Fibronectin fragments bind to and penetrate cartilage tissue resulting in proteinase expression and cartilage damage. Biochim Biophys Acta 1993, 1182:189-196.
6. Homandberg GA, Meyers R, Williams JM. Intraarticular injection of fibronectin fragments causes severe depletion of cartilage proteoglycans in vivo. J Rheumatol 1993, 20:1378-1382.
7. Homandberg GA, Meyers R, Xie DL. Fibronectin fragments cause chondrolysis of bovine articular cartilage slices in culture. J Biol Chem 1992, 267:3597-3604.
8. Kapila YL, Kapila S, Johnson PW. Fibronectin and fibronectin fragments modulate the expression of proteinases and proteinase inhibitors in human periodontal ligament cells. Matrix Biol 1996, 15:251-261.
9. Kapila YL, Lancero H, Johnson PW. The response of periodontal ligament cells to fibronectin. J Periodontol 1998, 69:1008-1019.
10. Kapila YL, Niu J, Johnson PW. The high affinity heparin-binding domain and the V region of fibronectin mediate invasion of human oral squamous cell carcinoma cells in vitro. J Biol Chem 1997, 272:18932-18938.
11. Kapila YL, Wang S, Dazin P, Tafolla E, Mass MJ. The heparin-binding domain and V region of fibronectin regulate apoptosis by suppression of p53 and c-myc in human primary cells. J Biol Chem 2002, 277:8482-8491.
12. Kapila YL, Wang S, Johnson PW. Mutations in the heparin binding domain of fibronectin in cooperation with the V region induce decreases in pp125(FAK) levels plus proteoglycan-mediated apoptosis via caspases. J Biol Chem 1999, 274:30906-30913.
13. Tafolla E, Wang S, Wong B, Leong J, Kapila YL. JNK1 and JNK2 oppositely regulate p53 in signaling linked to apoptosis triggered by an altered fibronectin matrix: jNK links FAK and p53. J Biol Chem 2005, 280:19992-19999.
14. Xie DL, Meyers R, Homandberg GA. Fibronectin fragments in osteoarthritic synovial fluid. J Rheumatol 1992, 19:1448-1452.
15. Dai R, Iwama A, Wang S, Kapila YL. Disease-associated fibronectin matrix fragments trigger anoikis of human primary ligament cells: p53 and c-myc are suppressed. Apoptosis 2005, 10:503-512.
16. Forsyth CB, Pulai J, Loeser RF. Fibronectin fragments and blocking antibodies to alpha2beta1 and alpha5beta1 integrins stimulate mitogen-activated protein kinase signaling and increase collagenase 3 (matrix metalloproteinase 13) production by human articular chondrocytes. Arthritis Rheum 2002, 46:2368-2376.
17. Gemba T, Valbracht J, Alsalameh S, Lotz M. Focal adhesion kinase and mitogen-activated protein kinases are involved in chondrocyte activation by the 29-kDa amino-terminal fibronectin fragment. J Biol Chem 2002, 277:907-911.
18. Homandberg GA, Costa V, Wen C. Fibronectin fragments active in chondrocytic chondrolysis can be chemically cross-linked to the alpha5 integrin receptor subunit. Osteoarthritis Cartilage 2002, 10:938-949.
19. Yasuda T, Kakinuma T, Julovi SM. COOH-terminal heparin-binding fibronectin fragment induces nitric oxide production in rheumatoid cartilage through CD44. Rheumatology (Oxford) 2004, 43:1116-1120.
20. Brooks CL, Gu W. p53 ubiquitination: Mdm2 and beyond. Mol Cell 2006, 21:307-315.
21. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000, 408:307-310.
22. Brooks CL, Gu W. Ubiquitination, phosphorylation and acetylation: the molecular basis for p53 regulation. Curr Opin Cell Biol 2003, 15:164-171.
23. Yang Y, Li CC, Weissman AM. Regulating the p53 system through ubiquitination. Oncogene 2004, 23:2096-2106.
24. Pickart CM. Mechanisms underlying ubiquitination. Annu Rev Biochem 2001, 70:503-533.
25. Weissman AM. Themes and variations on ubiquitylation. Nat Rev Mol Cell Biol 2001, 2:169-178.
26. Lavin MF, Gueven N. The complexity of p53 stabilization and activation. Cell Death Differ 2006, 13:941-950.
27. Bergamini E. Protein degradation and modification. Introduction and overview. Ann N Y Acad Sci 1992, 663:43-47.
28. Trombetta ES, Parodi AJ. Quality control and protein folding in the secretory pathway. Annu Rev Cell Dev Biol 2003, 19:649-676.
29. Chauhan D, Hideshima T, Anderson KC. Targeting proteasomes as therapy in multiple myeloma. Adv Exp Med Biol 2008, 615:251-260.
30. Dahlmann B. Role of proteasomes in disease. BMC Biochem 2007, 8(suppl 1):S3.
31. Daviet L, Colland F. Targeting ubiquitin specific proteases for drug discovery. Biochimie 2008, 90:270-283.
32. Harris SL, Levine AJ. The p53 pathway: positive and negative feedback loops. Oncogene 2005, 24:2899-2908.
33. Momand J, Zambetti GP, Olson DC, George D, Levine AJ. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992, 69:1237-1245.
34. Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 1992, 358:80-83.
35. Ruoslahti E. Fibronectin and its receptors. Annu Rev Biochem 1988, 57:375-413.